Episurf Medical publishes prospectus regarding the admission to trading of new shares of series B on Nasdaq Stockholm
This press release may not be made public, published or distributed, directly or indirectly, in whole or in part, within or to the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or any other jurisdiction where such action would be unlawful or subject to legal restrictions.Episurf Medical AB (publ) (“Episurf Medical” or the “Company”) has on 14 October 2021, based on the authorisation granted by the Annual General Meeting on 10 May 2021, carried out a directed issue of 44,408,108 new shares of series B (the “Share Issue”). The Share